Aton Pharma Acquires Marketing Rights to Preservative-Free Timolol Product Line from Merck
February 25, 2009
Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced it has acquired the U.S. marketing rights to the TIMOPTIC(R) product line from Merck & Co., Inc. TIMOPTIC (timolol maleate) is a non-selective beta-adrenergic receptor blocking agent indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. As many as 2.25 million Americans suffer from open-angle glaucoma.
The U.S. TIMOPTIC product line includes TIMOPTIC(R) (timolol maleate) Ophthalmic Solution, TIMOPTIC (timolol maleate ophthalmic solution) in OCUDOSE(R) (sterile ophthalmic unit dose dispenser) and TIMOPTIC-XE(R) (timolol maleate ophthalmic gel forming solution) Ophthalmic. TIMOPTIC in OCUDOSE(R) is the only preservative-free medication for glaucoma available in the U.S.
Aton’s market research indicates that more than 60% of ophthalmologists are unaware that preservative-free preparations of timolol are available.
Aton Pharma also provides the dry eye medication LACRISERT(R) (hydroxypropyl cellulose ophthalmic insert), a preservative-free, once-daily, sustained release prescription insert indicated for moderate to severe dry eye, that helps to retain moisture, stabilize the tear film, and lubricate the eye.
Read the full press release.
Comments
Jump down to form below to submit your own comments
